NCT05257213 Heparin Solution Versus Anti-adhesion Barrier Gel for Intrauterine Adhesions Prevention After Operative Hysteroscopy
| NCT ID | NCT05257213 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nadezhda Women's Health Hospital |
| Condition | Intrauterine Adhesion |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-02-14 |
| Primary Completion | 2026-02-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2022-02-14 with a primary completion date of 2026-02-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to compare the efficacy of intrauterine application of heparin solution to the use of hyaluronic acid barrier gel for the prevention of intrauterine adhesion formation after operative hysteroscopy.
Eligibility Criteria
Inclusion Criteria: * female sex * indication for operative hysteroscopy including one or more of the following: * infertility, * irregular bleeding, * oligo-/amenorrhea, * Asherman syndrome, * G0-G3 fibroids, * dysmorphic uterus. Exclusion Criteria: * ongoing pregnancy, * genital cancer, * pelvic inflammatory disease, * excessive uterine bleeding.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05257213 clinical trial?
This trial is open to female participants only, aged 25 Years or older, up to 50 Years, studying Intrauterine Adhesion. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05257213 currently recruiting?
Yes, NCT05257213 is actively recruiting participants. Contact the research team at g.stamenov1@abv.bg for enrollment information.
Where is the NCT05257213 trial being conducted?
This trial is being conducted at Sofia, Bulgaria, Sofia, Bulgaria.
Who is sponsoring the NCT05257213 clinical trial?
NCT05257213 is sponsored by Nadezhda Women's Health Hospital. The trial plans to enroll 100 participants.